Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integration
Analysis of the current clinical landscape of mPC Italy to identify gaps and opportunities for improvement. Patient identification and enrollment Blood sample collection and plasma purification ctDNA extraction and NGS analysis of homologous recombination repair (HRR) genes. Clinical Real-World Data (RWD) and molecular analysis data collection Testing algorithm development based on collected data Finalization and sharing of a best practice model for diagnostic procedures in mPC patients
Study Type
OBSERVATIONAL
Enrollment
125
European Institute of oncology
Milan, Italy
RECRUITINGValidation of an assay for homologous recombination repair (HRR) gene mutation testing using liquid biopsy
Validation of an assay for homologous recombination repair (HRR) gene mutation testing using liquid biopsy in patients with metastatic prostate cancer (mPC) whose tumor tissue is inadequate or unavailable for molecular testing.
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.